Your Article Summary
See Latest ArticlesRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
New England Journal of Medicine, 11/20/08
Ridker PM et al. - Authors hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment. In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Related Articles
Serum amyloid A and C-reactive protein concentrations are differently associated with markers of autoimmunity in patients with primary Sjogren's syndrome
Journal of Rheumatology, 10/19/09
Relevance Score: 68%
C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction
Cardiovascular Research, 11/19/09
Relevance Score: 67%
The C-Reactive Protein Levels in Left Ventricular Dysfunction of Different Etiology
Inflammation & Allergy - Drug Targets, 10/09/09
Relevance Score: 66%
Increased C-reactive protein levels in overweight and obese women taking exogenous hormones: the United Kingdom Womens Heart Study (UKWHS)
Clinical Endocrinology, 10/16/09
Relevance Score: 65%
C-reactive protein as a predictor of disease in smokers and former smokers: a review
International Journal of Clinical Practice, 10/12/09
Relevance Score: 65%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences
Vascular Health and Risk Management, 11/30/09
Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne
International Journal of Women's Health, 11/30/09
Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
Clinical Interventions in Aging, 11/30/09